Syntekabio will present its AI drug discovery platforms, DeepMatcher® and NEO-ARS™, at the UKC 2022 in Arlington on August 19. The event fosters collaboration between U.S. and Korean professionals in science and technology, aiming to connect entrepreneurs with industry leaders. DeepMatcher® and NEO-ARS™ are set to launch in September, enhancing drug discovery processes.
Syntekabio, a global leader in AI drug discovery, will showcase its advanced cloud platforms, DeepMatcher® and NEO-ARS™, at the US-Korea Conference (UKC) 2022 on August 19 in Arlington, Virginia. These platforms are set to be launched in September, enhancing drug discovery processes. The UKC event aims to promote collaboration between American and Korean professionals in science and engineering, providing a networking opportunity for entrepreneurs and investors.
The use of artificial intelligence in drug discovery is transforming the pharmaceutical industry by enabling faster and more efficient development of new therapies. Syntekabio, established in 2009 in South Korea, leverages AI and big data to create innovative solutions for drug development. The participation in UKC 2022 underscores Syntekabio’s commitment to fostering international partnerships and advancing the field of medicine through technology.
In conclusion, Syntekabio’s presentation at the UKC 2022 highlights the company’s innovative contributions to AI drug discovery. With upcoming platforms like DeepMatcher® and NEO-ARS™, Syntekabio aims to enhance therapeutic development and meet international healthcare needs. The event serves as a pivotal opportunity for collaboration between U.S. and Korean businesses, reinforcing the importance of cross-border partnerships.
Original Source: www.globenewswire.com
